CVM Halal Report | Practical Islamic Finance

Company Overview

Industries

Manufacturing
Pharmaceutical Products
Biological Products
Except Diagnostic Substances

Exchange

Next Earnings Date

Use of Interest

Reporting Date	Total Revenue	Total Operating Expense	Interest Income	Interest Expense	Interest Income Ratio	Interest Expense Ratio

Company Impact

Help us evaluate Cel-Sci Corp.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Justification for our Halal Rating

Contribute

Recent News & Updates

Nov. 07
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Oct. 22
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment
Oct. 01
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Sep. 16
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the T
Sep. 10
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sign In and continue reading this report

Create a free account and continue reading this report

Sign up for free and continue reading this report

Cel-Sci Corp.

Company Overview

Use of Interest

Company Impact

Justification for our Halal Rating

Recent News & Updates